Navigation Links
Shave biopsy is a safe and acceptable method for initial evaluation of melanoma
Date:5/23/2011

A shave biopsy is a reasonably safe and accurate method for the initial diagnosis of melanoma, according to a study published in the April issue of the Journal of the American College of Surgeons. In the past, some physicians have criticized shave biopsies for not providing accurate T (tumor) stage information, thereby complicating treatment planning.

"We conducted this study to determine the impact of shave biopsies on the initial staging of melanoma and their impact on the final treatment planning for patients," explained Jonathan S. Zager, MD, FACS, associate professor at the Moffitt Cancer Center, Tampa, FL, and lead author of the study. "Shave biopsies are commonly used by dermatologists, primary care physicians, and surgeons as a less invasive and more efficient means of biopsying suspicious lesions for diagnosis."

In the largest study to date, researchers at Moffitt Cancer Center and the University of Florida Shands Cancer Center, Gainesville, retrospectively analyzed 600 consecutive patients who underwent a shave biopsy for suspicious skin lesions between 2006 and 2009. They found presumptive pre-shave diagnosis of melanoma was suspected in only 25 percent of these patients. After definitive surgical wide excision was performed, 133 (22 percent) had residual melanoma in the surgical excision specimen. However, the detection of residual melanoma in these patients only resulted in subsequent upstaging in T-stage in a small group of 18 (3 percent) patients, showing that T-stage and depth data obtained through shave biopsy were accurate in 97 percent of all patients.

"The diagnosis of melanoma can be extremely challenging, even for the most experienced health care professional," Dr. Zager said. "Although traditional excisional biopsy remains the gold standard for the diagnosis of suspicious skin lesions, where a rim of normal appearing skin can be excised with the specimen (especially when melanoma is suspected), our results show shave biopsies may be used as a first-line evaluation for skin lesions with minimal impact on T-staging and definitive treatment options."

While there are advantages and disadvantages to consider when comparing excisional, punch, and shave biopsies of skin lesions, the disadvantages of shave biopsies remain largely cosmetic. Because shave biopsies don't require sutures for closure, a depressed, hypopigmented or hyperpigmented scar may sometimes occur. Punch biopsies present physicians with limitations with regard to the size of the biopsy tools available to accommodate an accurate biopsy, as best practices generally recommend excision of some normal appearing skin at the edges of the skin lesion in question.

According to the American Cancer Society, skin cancer accounts for almost half of all cancers in the United States. Melanoma, the most severe form of skin cancer, affected about 68,130 people in 2010 alone.


'/>"/>

Contact: Sally Garneski
pressinquiry@facs.org
312-202-5409
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Get a Better Shave in Less Time With New Waterless Shave Product
2. The Classic Shave Company Announces the Opening of Beverly Hills Shop
3. New technology fuses MRI, ultrasound to achieve targeted biopsy of prostate cancer
4. Closely monitoring low-risk prostate cancer, with biopsy, does not raise risk of death
5. Elastography helps identify patients who need biopsy
6. Virtual biopsy may allow earlier diagnosis of brain disorder in athletes
7. Gene expression test reduces need for invasive heart muscle biopsy
8. Routine breast cancer biopsy might predict lymph node cancer spread
9. Scientists design new anti-flu virus proteins using computational methods
10. Innovative screening method identifies possible new treatment for fatal childhood disease
11. Study finds diet plus exercise is more effective for weight loss than either method alone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... Maury Regional Health has announced a large-scale adoption of AccuVein ... devices, Maury Regional Medical Center is making vein visualization part of their standard of ... and more importantly, helps our staff members locate a vein that will provide good ...
(Date:8/16/2017)... ... 16, 2017 , ... A global leader in the treatment of clubfoot, ... 29 Indian states—bringing the country one step closer to eliminating clubfoot as a lifelong ... is on track to enroll 10,000 children in the clubfoot treatment program in this ...
(Date:8/16/2017)... ... ... Fusion Flix Inc., a Telly Award Winning, Non Profit Corporation has announced ... in a partnership with the Amazon Video Direct Streaming Distribution Platform. , Their content ... disc in 2018. Proceeds will be going to further health research. , Fusion ...
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class ... . , The healthcare industry in the United States has undergone major changes over ... of needing to have a doctor’s order to get a blood test or other ...
(Date:8/16/2017)... , ... August 16, 2017 , ... First Choice ... States, named Dr. Douglas J. Harrison, as the new Medical Director of its Sienna ... new facility Medical Director of our Sienna Plantation location,” said Dr. Michael (Derek) Caraway, ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... , July 26, 2017 E.I. Medical Imaging ... the Bimini SharkLab to custom design the worlds first ultrasound system ... sharks in their native habitat. In preparation for a ... Channel,s Shark Week, Dr. Guttridge approached EIMI with the ... diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... Sancilio Pharmaceuticals Company, Inc. (SPCI) today announced ... Altemia TM , an oral therapy for pediatric patients ... (SCD). The SCOT Trial, is a double-blind, placebo-controlled, dose-finding, ... Altemia TM in pediatric patients aged 5-17 years ... "The completion of ...
(Date:7/25/2017)... and CAMBRIDGE, Massachusetts , July ... specializing in repurposing drugs to treat rare nervous system diseases, ... to clinically develop and market the drug SOM0226 against transthyretin ... drug achieved very promising results in a Phase 2 study ... A new office in the United States ...
Breaking Medicine Technology: